Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 196

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 196
---
ences Ironwood Pharmaceuticals BioCryst Pharmaceuticals Mirati Therapeutcis Blueprint Medicines Madrigal Pharmaceuticals BridgeBio Pharma REGENXBIO CRISPR Therapeutics AG Sarepta Therapeutics Deciphera Pharmaceuticals Ultragenyx Pharmaceuticals Denali Therapeutics Vir Biotechnology Halozyme Therapeutics BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Ironwood Pharmaceuticals, and Madrigal Pharmaceuticals were added to the compensation peer group and Chemo Centryx, FibroGen, Novavax, amd Reata Pharmaceuticals were removed from the compensation peer group due to changes in our business complexity, employee base and market capitalization, as well as mergers, changes to business complexity, employee base and market capitalization among our prior peer group. The compensation study prepared by Compensia and presented in October 2023 provided an assessment of our compensation practices as compared to industry peers. Compensation levels for our executive officers, in the aggregate, were determined to be within the range of compensation provided to similarly placed executives and consistent with our compensation philosophy. Individual Compensation Elements In 2024, the principal elements of our executive compensation program were as follows: • base salary; • an annual cash incentive compensation opportunity; • long-term incentive compensation in the form of equity awards; • welfare and health benefits; and • post-employment compensation arrangements. Base Salary Base salary represents the fixed portion of the compensation of our executive officers, including our NEOs, and is an important element of compensation intended to attract and retain highly-talented individuals. Table of Contents 2025 PROXY STATEMENT 36

The initial base salaries for our executive officers were negotiated on an individual basis at the time of hire. Thereafter, using the competitive market data provided by its external compensation consultant, the Compensation Committee reviews and determines adjustments to the base salaries for each of our executive officers, including our NEOs, as part of its annual executive compensation review. In addition, the base salaries of our executive officers may be adjusted by the Compensation Committee in the event of a promotion or significant change in responsibilities. Generally, the Compensation Committee sets base salaries with reference to the competitive range of the market median of our compensation peer group and applicable executive compensation survey data, as well as its assessment of the factors described in “Governance of Executive Compensation Program — Compensation-Setting Process” above. The base salaries of our NEOs for fiscal 2024 and fiscal 2023 were as follows: Named Executive Officer Fiscal 2024 Base Salary Fiscal 2023 Base Salary Percentage Adjustment Christopher Anzalone President &